Social Media Ideas for Pharmacy Economics

<![CDATA[Who Pays for Tariff Driven Input Cost Increases?]]>

<![CDATA[Taking a Hard Look at Pharma's Traditional Margin Model]]>

<![CDATA[Pharma’s New Growth Equation: Smarter Deals, Stronger Science, Rising Costs]]>

The K-Shaped Pharmacy Shakeout: Consolidation in Cities, Lost Access in Rural America

By Bryce Platt, PharmD The United States has almost 8,000 fewer retail pharmacies than it did in 2018, and more than 2,000 closed in 2025 alone. Rite Aid has liquidated. Walgree...

<![CDATA[When Drug Pricing Becomes Trade Policy]]>

<![CDATA[The Retailization of Medicare Advantage: What Costco’s Entry Means for Pharma]]>

Who Will Pay for Prescription Drugs in 2034? Medicare's Surprising Rise in the Latest Government Forecasts

By Adam J. Fein, Ph.D. and Greis Kapexhiu In late June, the boffins at the Centers for Medicare & Medicaid Services (CMS) released the latest projections for U.S. spending on...

Kansas pharmacist awaits data, expects state to save millions from transparency under new law

TOPEKA — A Lawrence pharmacy is losing revenue under a bipartisan law that holds the pharmacy industry to new standards of transparency. That is what Will Anderson, owner of Orchar...

2025 Gross-to-Net Realities at Eight Top Drugmakers: The Net Pricing Drug Channel Emerges

By Adam J. Fein, Ph.D. Every year, Drug Channels reviews drug pricing trends at the largest pharmaceutical manufacturers. This year's disclosures provide early evidence that the...

<![CDATA[FDA's New Frontier: Drug Pricing Enters the Conversation]]>

Drug Channels News Roundup, August 2026: 340B Rebate Model v2, Patients Feeling Drug Costs, Specialty Drug Spending Driv...

By Bryce Platt, PharmD Kids are heading back to school, but the drug channel never stops handing out homework. Fortunately, we did some of the research prep for you. In this...

The Private Label Biosimilar Paradox in Medicare Part D

By Tyler Novotny and Bryce Platt PBM-affiliated private label biosimilars would seem to have a built-in formulary advantage. But for ustekinumab, that advantage has not carrie...

Drug Channels News Roundup, August 2026: 340B Rebate Model v2, Patients Feeling Drug Costs, Specialty Drug Spending Driv...

Drug Channels News Roundup, August 2026: 340B Rebate Model v2, Patients Feeling Drug Costs, Specialty Drug Spending Drivers, Impact on Coverage from the IRA, and a Drug Price Adven...

Major PBMs agree to offer TrumpRx pricing information to members

The Pharmaceutical Care Management Association announced Thursday that its members had reached an agreement with the feds to offer information on cash prices available through Trum...

A Prescription for Drug Costs: Inject Transparency and Improve Accessibility

Drug spending continues to grow, but that doesn’t mean that everyone is getting the medicines that they need. A panel at MedCity News’ Bullseye event discussed the evolution of the...

<![CDATA[The Current Status of the 340B Program]]>

<![CDATA[Patient Access, Innovation, and the Global Cost of MFN]]>

Ukraine pharmacy sales rise 15% by value, fall nearly 6% by volume in H1 2026

Pharmacy sales in Ukraine in January-June 2026 rose by 15% in monetary terms compared with the same period in 2025, to nearly UAH 121 billion, while in volume terms they decreased...

To the editor: Drug shortages not a license to price gouge

You go to your pharmacy to pick up a routine refill, and the pharmacist tells you it’s out of stock. A supply chain problem somewhere else in the country left the shelves bare. The...

Employers cut GLP-1 coverage as pharmacy costs soar

Plan sponsors pushback on cost drivers, PBM evaluation a crucial calling card for benefits brokers

Future governments told to spend more on medicines and reap big savings

An economic analysis commissioned by Business NZ has found every additional dollar spent on medicines delivers an almost $2 economic return.

Amazon Pharmacy partners with eNavvi to provide real-time medication pricing, delivery info to providers

The partnership allows providers to see current pricing and stock for prescriptions, including cash pricing versus estimated insurance copays, and delivery estimates.

<![CDATA[Managing the Uncertainty of Inventory, Staffing, and Formulary Planning Around Peptides?]]>

The 340B Program Hit $100 Billion in 2025: Has It Become Too Big to Reform?

By Adam J. Fein, Ph.D.The 340B Drug Pricing Program continues to redefine the meaning of "skyrocketing." For 2025, discounted purchases under the 340B program reached an astound...